Royalty Pharma plc Class A Ordinary Shares RPRX
$58.60
+0.07%
at last close
Market Cap$26.37 billion
P/E Ratio31.17
Div Yield1.60%
Volume1.60M
52-Week Range
$34.08$60.44
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $59.17 (+1.0% upside)
Key Stats
- Today's Range
- $57.72 – $58.78
- 50-Day Range
- $51.15 – $60.44
- 52-Week Range
- $34.08 – $60.44
- Volume
- 1.60 million shs
- Average Volume
- 2.85 million shs
- Market Cap
- $26.37 billion
- P/E Ratio
- 31.17
- Dividend Yield
- 1.60%
Valuation
- P/E Ratio
- 31.17
- Price / Book
- 2.69
- Price / Sales
- 10.40
Dividend
- Dividend Yield
- 1.60%
- Annual Dividend
- $0.94
- Payout Ratio
- 50.00%
- Ex-Dividend Date
- 2026-08-14
Short Interest
- Short Interest
- 0.34%
- Days to Cover
- 2.12
Financials (TTM)
- Revenue
- $2.54 billion
- Net Income
- $1.35 billion
- Net Margin
- 53.23%
- Return on Equity
- 13.79%
- Debt-to-Equity
- 0.92
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Related Stocks
Compare head-to-head: RPRX vs LLY·RPRX vs JNJ·RPRX vs ABBV·RPRX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.